Are We Abandoning IQ and OQ? - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Are We Abandoning IQ and OQ?
New standards may overlook critical qualification needs.

Pharmaceutical Technology
Volume 33, Issue 11, pp. 106-105

Final thoughts

Over the years, the practice of validation has been truncated, revised, and reinvented. The old standbys of IQ, OQ, and PQ have been criticized by some as not being in step with current technology and practice. Many in industry argued that most people understood GXP, including GEP. Although the industry may have matured in this sense, human nature may not have. Quality problems and recalls still occur.

FDA has not entirely abandoned the concept of qualification as pointed out in its draft guidance on process validation. But relying solely on verification processes and eliminating the role of QA and QUs is not enough to ensure quality. The current situation is further complicated by the variety of unharmonized approaches and standards throughout the global industry. Even within existing regulations, there is inconsistency of meaning and implementation.

Some potential solutions include:
  • Involving QA from the onset to participate in the review and acceptance of vendor documentation and the commissioning and verification of related documentation.
  • Commissioning and verification testing for every applicable system. Testing should be completed with a QA reviewer and approved in a closeout report
  • Above all, requalification and revalidation should take place as needed and when necessary.

Louis A. Angelucci is the director of corporate validation at MedImmune, One MedImmune Way, Gaithersburg, MD 20878, tel. 301.398.2949,


1. FDA, Draft Guidance for Industry—Process Validation: General Principles and Practices (Rockville, MD, Nov. 2008).

2. ASTM, Standard E2500-07 Standard Guide for Specification, Design, and Verification of Pharmaceutical and Biopharmaceutical Manufacturing Systems and Equipment (West Conshohocke, PA, 2007).


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here